Press Release
For Immediate Release – June 8, 2009
Tranzyme Pharma to Present Multiple Applications of its Proprietary Drug Discovery Technology at the 21st American Peptide Society Symposium
RESEARCH TRIANGLE PARK, N.C. (June 8, 2009) – Tranzyme Pharma today announced that Mark L. Peterson, Ph.D., Vice President, Intellectual Property and Operations, will present new results emanating from application of the Company’s MATCH™ technology platform to the discovery of drugs for gastrointestinal (GI) diseases at the upcoming 21st American Peptide Society Symposium being held from June 7-12, 2009. Dr. Peterson’s presentation will take place on Tuesday, June 9, 2009 at 4:10 p.m. ET in the University of Indiana Auditorium, Bloomington, Indiana.
In his presentation entitled “From Libraries of Macrocyclic Peptidomimetics to Gastrointestinal Drugs”, Dr. Peterson will discuss the use of MATCH™ for the discovery of small molecule clinical candidates that target the ghrelin receptor (TZP-101 and TZP-102) or motilin receptor (TZP-201). Ghrelin and motilin are G protein-coupled receptors intimately involved in the normal regulation of the GI tract.
About MATCH™
Tranzyme’s pipeline of products originates from its proprietary Macrocyclic Template Chemistry (MATCH™). MATCH™ is a drug design and medicinal chemistry platform which exploits the potential of macrocycles, a distinct compound class that displays the favorable characteristics exhibited by large biomolecules, while maintaining the benefits typically associated with small molecule drugs. In addition to Tranzyme’s current internal development focus, MATCH™ has broad applicability in the treatment of other diseases that involve hormones, peptides, ion channels or protein-protein interaction pathways.
About TZP-101
TZP-101, Tranzyme’s intravenous ghrelin agonist, is the first product from the Company’s internal drug discovery efforts. TZP-101 is in clinical development for the treatment of postoperative ileus (POI) and gastroparesis in acute care settings and has the potential to treat other conditions requiring administration of intravenous prokinetic agents, including post-operative nausea and vomiting, and other acute motility-related disorders. The safety and pharmacokinetic profiles of TZP-101 have been extensively characterized in healthy subjects and patients across multiple dose levels, and the GI prokinetic properties of the compound have been well established in various animal models and humans.
About TZP-102
TZP-102 is a novel, orally administered prokinetic agent that acts by a mechanism distinct from previously developed products for gastrointestinal (GI) motility disorders. TZP-102 is a second generation agonist of the ghrelin receptor (which is distributed in both the upper and lower GI tract). TZP-102 is in clinical development for gastroparesis and has the potential to treat other chronic GI and motility disorders, including GERD, functional dyspepsia, opioid bowel dysfunction and irritable bowel syndrome with constipation.
About TZP-201
TZP-201 is a first-in-class, highly potent and selective motilin antagonist for the treatment of gastrointestinal hypermotility disorders of various origins including chemotherapy-induced diarrhea (CID). In preclinical animal studies, TZP-201 has been demonstrated to dose-dependently prevent or substantially mitigate irinotecan-induced diarrhea under conditions mimicking the clinical situation. As with the other candidates derived using MATCH™, TZP-201 exhibits excellent pharmacokinetic and safety profiles.
About Tranzyme Pharma
Tranzyme Pharma is a late stage biopharmaceutical company engaged in the discovery and development of first-in-class small molecule therapeutics for the treatment of both acute care (hospital-based) and chronic indications with significant unmet medical needs. For more information on Tranzyme, please visit: http://www.tranzyme.com.
